Skip to main content

Bass Group Buys Stake in Human Genome Sciences

Premium

ROCKVILLE, Md.--A group of investors including several members of the Bass family purchased a 14 percent stake in the genetic research firm Human Genome Sciences here this summer, according to a filing made last month with the Securities and Exchange Commission. The filing showed that between June 8 and August 8, the group bought 568,000 shares at prices ranging from $30.42 to $31.02 per share, for investment purposes. Human Genome Sciences is involved in the discovery of human and microbial genes for the prevention, detection, treatment, and cure of disease. The firm develops products both on its own and in partnership with other companies.

Filed under

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.